Cyberknife治疗纵隔转移淋巴结的临床分析  被引量:2

Clinical analysis of cyberknife stereotactic ablative radiotherapy for malignant tumors with metastases of mediastinal lymph nodes

在线阅读下载全文

作  者:王娟[1] 袁智勇[1] 刘春雷[1] 王宝虎[1] 宋勇春[1] 王平[1] 

机构地区:[1]天津医科大学附属肿瘤医院放疗科,天津市肿瘤防治重点实验室,天津市300060

出  处:《中国肿瘤临床》2013年第5期280-283,共4页Chinese Journal of Clinical Oncology

摘  要:目的:评价射波刀(Cyberknife)治疗纵隔转移淋巴结的临床价值。方法:分析射波刀治疗39例恶性肿瘤纵隔淋巴结转移患者的临床资料。病灶共计49个,直径1.5~4.3 cm。治疗剂量12~60 Gy,分割1~10次。结果:治疗后随访3~67个月(中位数20个月),胸闷、气短等症状缓解率83.3%。49个病灶CR、PR、SD分别为29、15、5个,有效率90%。1、2年局控率为100%、91%,1、2年生存率分别为84.6%、68.3%。急性期无反应者25例,1~2级、3~4级放疗反应分别为11例、3例。既往行胸部放疗、隆突下及气管食管沟病灶、放疗前后1个月行化疗者放疗不良反应发生率较高(P=0.014、0.007、0.039),反应组食管5 mL平均照射剂量30.62 Gy明显高于无反应组15.5 Gy(P=0.045)。结论:射波刀为纵隔淋巴结转移者提供了安全有效的治疗手段。Objective: This work aimed to evaluate the clinical results of the cyberknife stereotactic ablative radiotherapy (SABR) treatment of 39 patients suffering from mediastinal lymph-node metastases of malignant tumors. Methods: Cyberknife SABR was con- secutively conducted on 39 cancer patients with 49 mediastinal nodal metastases. Planning target volume ranged from 3.7 ml to 78.5 ml (median: 12.3 ml), and total prescribed dosage ranged from 12 Gv to 60 Gy with 1 fraction to 10 fractions. Results: Follow-up assessment was performed from 3 mos to 67 mos (median: 20). The most commonly observed toxicity was Grade 1/2 tracheal and esophageal injuries, which occurred in 11 of the 39 patients. Grade 3/4 toxicity occurred in 3 of the 39 patients. Patients with dyspnea, superior vena cava syndrome, and chest pain achieved significant improvements in health status (response rate: 83.3%). Total effective rate (complete and partial response) was 90% for the 49 discrete lesions (29 complete responses, 15 partial responses, and 5 stable diseases), The 1 and 2 yr overall survival rates were 84.6% and 68.3%, respectively. Patients with metastasized nodes below 3 cm in diameter attained superior overall survival times compared with those with metastasized nodes above 3 cm in diameter (P=0.029). Conclusion: Cyberknife SABR for the mediastinal metastases carcinoma showed a favourable outcome and minimal toxicity.

关 键 词:纵隔转移淋巴结 射波刀 立体定向放射治疗 

分 类 号:R734.5[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象